TAT-fused IP3R-derived peptide enhances cisplatin sensitivity of ovarian cancer cells by increasing ER Ca(2+) release

Ovarian cancer is the most common gynecological malignancy. At present, cisplatin is used to treat ovarian cancer; however, the development of cisplatin resistance during therapy is a common obstacle to achieving favorable outcomes. Recently, the B-cell lymphoma 2 (Bcl-2) BH4 domain has been reporte...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Qi, Xu, Ye, Gao, Weinan, Zhang, Yong, Su, Jing, Liu, Yanan, Guo, Yuting, Dou, Minghan, Hu, Kebang, Sun, Liankun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752180/
https://www.ncbi.nlm.nih.gov/pubmed/29207009
http://dx.doi.org/10.3892/ijmm.2017.3260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752180/
https://www.ncbi.nlm.nih.gov/pubmed/29207009
http://dx.doi.org/10.3892/ijmm.2017.3260

Ejemplares similares